Literature DB >> 26777918

Large-scale screening for somatic mutations in lung cancer.

Rafael Rosell1, Niki Karachaliou2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 26777918     DOI： 10.1016/S0140-6736(15)01125-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  37 in total

Review 1.  Possible application of circulating free tumor DNA in non-small cell lung cancer patients.

Authors:  Niki Karachaliou; Aaron E Sosa; Miguel Angel Molina; Margarita Centelles Ruiz; Rafael Rosell
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

Review 2.  Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients.

Authors:  Cristina Aguado; Ana Giménez-Capitán; Niki Karachaliou; Ana Pérez-Rosado; Santiago Viteri; Daniela Morales-Espinosa; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2016-10

Review 3.  Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis.

Authors:  José Luís González-Larriba; Martín Lázaro-Quintela; Manuel Cobo; Manuel Dómine; Margarita Majem; Rosario García-Campelo
Journal:  Transl Lung Cancer Res       Date:  2017-12

Review 4.  Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment.

Authors:  Feng Li; Binchi Liao; Ting Wang; Tingting Qi; Yixin Wang
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

Review 5.  KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients.

Authors:  Mónica Garzón; Sergi Villatoro; Cristina Teixidó; Clara Mayo; Alejandro Martínez; Maria de Los Llanos Gil; Santiago Viteri; Daniela Morales-Espinosa; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2016-10

6.  Multi-targeted tyrosine kinase inhibitors as third-line regimen in advanced non-small cell lung cancer: a network meta-analysis.

Authors:  Zhonghan Zhang; Yuanyuan Zhao; Feiteng Lu; Xue Hou; Yuxiang Ma; Fan Luo; Kangmei Zeng; Shen Zhao; Yaxiong Zhang; Ting Zhou; Yunpeng Yang; Wenfeng Fang; Yan Huang; Li Zhang; Hongyun Zhao
Journal:  Ann Transl Med       Date:  2019-09

Review 7.  Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment.

Authors:  Martyna Filipska; Rafael Rosell
Journal:  Mol Oncol       Date:  2021-05-26       Impact factor: 6.603

8.  Combination of epidermal growth factor receptor mutation and the presence of high-grade patterns is associated with recurrence in resected stage I lung adenocarcinoma.

Authors:  Yasuto Kondo; Junji Ichinose; Hironori Ninomiya; Kohei Hashimoto; Yosuke Matsuura; Masayuki Nakao; Yuichi Ishikawa; Sakae Okumura; Yukitoshi Satoh; Mingyon Mun
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-07-09

9.  Impact of clinical features of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients on osimertinib efficacy.

Authors:  Chiara Lazzari; Vanesa Gregorc; Mariacarmela Santarpia
Journal:  J Thorac Dis       Date:  2019-11       Impact factor: 2.895

10.  Evaluation of dynamic image progression of minimally invasive and preinvasive lung adenocarcinomas.

Authors:  Tianxiang Chen; Xiaocheng Zhang; Alessio Campisi; Angelo Paolo Ciarrocchi; Andrea Dell'Amore; Liwei Song; Yunhai Yang; Chengshui Chen; Qingquan Luo
Journal:  Ann Transl Med       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.